The Gujarat Kidney and Super Specialty IPO received a strong response on its opening day, with 90% subscription led by robust retail participation. While grey market signals point to a steady listing, analysts have flagged valuation concerns and advised caution given the company’s aggressive expansion plans and premium pricing.